Teva in US agrees to 2017 for Vytorin generic, as Merck has other pending cases
12 July 2011
Nancy Faigen
Please Login to read the full article.
12 July 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Indian firms lead para IV charge, lock in key first-to-file opportunities
- Medicines Co shares rise 12% on US settlement with Teva on Angiomax patents
- Teva, Mylan settle litigation over generic Nuvigil, allowing US entry by 2016
- US FDA snubs Merck's ezetimibe/atorvastatin combo statin pill
COMMENT
Other Informa Comment
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
